…Martin and his team at St George Street, a UK-based biomedical research charity. The drug was originally developed for another indication by Astra Zeneca, who have agreed to provide the…
Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease….
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The…
…and nanotechnologies New therapeutic modalities ‘Omics Precision medicine for drug discovery Presentation, award opportunities and submission deadlines Live talks include real-time Q&A and opportunities for speakers to connect with participants,…
…adding that systematically analysing the data available on targets, drugs and disease mechanisms from data repositories and academic papers takes researchers over a year on average. “As so many scientists…
…of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells, resulting in greater efficacy, tolerability and the ability to treat more cancer patients; Semarion, a University…
…on the repeated clinical trial failures in neurogenerative diseases such as Alzheimer’s, the solution aims to improve the process of clinical trial screening and speed up drug discovery in diseases…
…inhibition from 92 crystal structures, Decoding SARS-CoV-2 transmission, evolution and ramification on COVID-19 diagnosis, vaccine, and medicine, Potentially highly potent drugs for 2019-nCoV, and Machine intelligence design of 2019-nCoV drugs…
Evotec and Centogene have expanded their drug discovery partnership related to the protein target glucocerebrosidase (GBA) with a focus on Gaucher disease. This is a genetic and relatively common lysosomal…
…a highly potent antiviral agent. BOLD-100 is a first-in-class ruthenium-based small molecule drug which selectively inhibits stress-induced upregulation of the chaperone protein GRP78. In cancer, GRP78 plays a critical role…
…are able to respond differently to their own DNA and to genetic material from a pathogen – and avoid attacking the wrong target. Their discovery, published in a paper in…
Enterprise Therapeutics is a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease. It has successfully dosed the…
…help for anticancer drug research. In addition, they also successfully demonstrated monitoring of mitochondria membrane potential in cells of brown adipose tissue, rich in mitochondria. Its stimulation could help cure…
…and result in impaired autophagy, which leads to the accumulation of aggregates. Our goal is to find small molecules or drug pathways and to develop these for multiple neurodegenerative diseases.”…
…2, or MacTel. The work was published in the New England Journal of Medicine. However, serine restriction or drug treatments for tumour therapy would not require the prolonged treatments that…
…clinical applications would find this tool very useful, and the level of precision could eventually lead to the discovery of specific cells or targets that are candidates for therapeutic intervention.”…
